| Anlotinib associated thyroid dysfunction: a real-world study |
| Received:August 29, 2021 Revised:March 27, 2022 Click here to download the full text |
| Citation of this paper:LI Fang,ZHANG Xiu-ping,LI Zhi-yong,LIU Tian-shu,ZHOU Yu-hong,WANG Zhi-ming.Anlotinib associated thyroid dysfunction: a real-world study[J].Chinese Journal of Clinical Medicine,2022,29(3):421-425 |
| Hits: 1067 |
| Download times: 299 |
| Author Name | Affiliation | E-mail | | LI Fang | Department of Medical Oncology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen 361015, Fujian, China | | | ZHANG Xiu-ping | Department of Medical Oncology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen 361015, Fujian, China | | | LI Zhi-yong | Department of Medical Oncology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen 361015, Fujian, China | | | LIU Tian-shu | Department of Medical Oncology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen 361015, Fujian, China
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China | | | ZHOU Yu-hong | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China | zhou.yuhong@zs-hospital.sh.cn | | WANG Zhi-ming | Department of Medical Oncology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen 361015, Fujian, China
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China | wang.zhiming@zs-hospital.sh.cn |
|
| Abstract:Objective To explore the incidence of thyroid dysfuction in anlotinib treated malignant tumor patients in real world. Methods The data of 146 patients with malignant tumors treated with arotinib for more than two courses in Xiamen Branch, Zhongshan Hospital, Fudan University from July 2019 to July 2020 were collected, and the thyroid functions were analyzed. Results Among 146 patients, 110 patients had normal thyroid function. The incidence rate of newly-diagnosed thyroid dysfunction was 38.2% (42/110) during follow-up, including 19.1%(21/110) with hypothyroidism, 14.5%(16/110) with subclinical hypothyroidism, and 3.4%(5/110) wih hyperthyroidism, they were all Grade 1/2. 92.6% of these abnormalities occurred within 6 months after the initial treatment of anlotinib. No patients altered antineoplastic therapy because of hypothyroidism. Conclusion Hypothyroidism is common in the real-world application of anlotinib, but the occurrence of hypothyroidism does not affect antineoplastic therapy. |
| keywords:targeted therapy anlotinib thyroid function |
| HTML View Full Text View/Add Comment Download reader |
|
|
|